Effects of guanine, inosine, and xanthine nucleotides on β2- adrenergic receptor/G(s) interactions: Evidence for multiple receptor conformations

Molecular Pharmacology

Volumn 56, Issue 2, 1999, Pages 348-358

  Seifert, Roland ^a,b   Gether, Ulrik ^c   Wenzel Seifert, Katharina ^b   Kobilka, Brian K ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA 2 ADRENERGIC RECEPTOR; GUANINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; HYBRID PROTEIN; INOSINE; INOSINE TRIPHOSPHATE; XANTHINE; XANTHOSINE;

ANIMAL CELL; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

EID: 0032770658     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.2.348     Document Type: Article

References (44)

1. Albrecht E, Samovilova NN, Oswald S, Baeger I and Berger H (1998) Nociceptin (orphanin FQ): High-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5′-O-(γ-thio)-triphosphate binding in rat brain membranes. J Pharmacol Exp Ther 286:896-902.
2. Bilezikian JP and Aurbach GD (1974) The effects of nucleotides on the expression of β-adrenergic adenylate cyclase activity in membranes from turkey erythrocytes. J Biol Chem 249:157-161.
3. Blake AD, Bot G, Freeman JC and Reisine T (1997) Differential opioid agonist regulation of the mouse μ opioid receptor. J Biol Chem 272:782-790.
4. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand J-P, Le Fur G and Casellas P (1997) A selective inverse agonist for central cannbinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
5. 8 vesicles. J Biol Chem 261:1656-1664.
6. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865-16873.
7. 3H-Naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: Evidence for G-protein-dependent antagonist binding. J Pharmacol Exp Ther 286:376-381.
8. i proteins: Comparisons of their contributions to GTPase activity and signal transduction and analysis of receptor-G protein activation stoichiometry. J Biol Chem 273:10367-10375.
9. Cassel D and Selinger Z (1976) Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim Biophys Acta 452:538-651.
10. Cassel D and Selinger Z (1977a) Activation of turkey erythrocyte adenylate cyclase and blocking of the catecholamine-stimulated GTPase by guanosine 5′-(γ-thio)triphosphate. Biochem Biophys Res Commun 77:868-873.
11. 3H]-Gpp(NH)p from turkey erythrocyte adenylate cyclase. J Cyclic Nucleotide Res 3:11-22.
12. Chidiac P, Hebert TE, Valiquette M, Dennis M and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499.
13. De Lean AJ, Stadel M and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255:7108-7117.
14. o in reconstituted phospholipid vesicles. J Biol Chem 264:3909-3915.
15. Gether U and Kobilka BK (1998) G-protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273:17979-17982.
16. Gether U, Lin S and Kobilka BK (1995) Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 270:28268-28275.
17. Gilman AG (1987) G proteins: Transducers of receptor-generated signals. Annu Rev Biochem 56:615-649.
18. Hilf G, Kupprion C, Wieland T and Jakobs KH (1992) Dissociation of guanine 5′-[γ-thio]triphosphate from guanine-nucleotide-binding regulatory proteins in native cardiac membranes: Regulation by nucleotides and muscarinic acetylcholine receptors. Eur J Biochem 204:725-731.
19. Iiri T, Farfel Z and Bourne HR (1998) G-protein diseases furnish a model for the turn-on switch. Nature (Lond) 394:35-38.
20. Keith D, Murray SR, Zaki P, Chu PC, Lissin DV, Kang L, Evans CE and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
21. Kelleher DJ, Dudycz LW, Wright GE and Johnson GL (1986) Ability of guanine nucleotide derivatives to bind and activate bovine transducin. Mol Pharmacol 30:603-608.
22. Kenakin T (1996) Receptor conformational induction versus selection: All part of the same energy landscape. Trends Pharmacol Sci 16:256-258.
23. i-proteins in HL-60 leukemia cell membranes. Biochem Pharmacol 54:551-662.
24. Kobilka BK (1992) Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15:87-114.
25. Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
26. Matesic DF, Manning DR, Wolfe BB and Luthin GR (1989) Pharmacological and biochemical characterization of complexes of muscarinic acetylcholine receptor and guanine nucleotide-binding protein. J Biol Chem 264:21638-21645.
27. Neubig RR (1994) Membrane organization in G-protein mechanisms. FASEB J 8:939-946.
28. Noel JP, Hamm HE and Sigler PB (1993) The 2.2 [Angst] crystal structure of transducin-α complexed with GTPγS. Nature (Lond) 366:654-663.
29. Northup JK, Smigel MD and Gilman AG (1982) The guanine nucleotide activating site of the regulatory component of adenylate cyclase: Identification by ligand binding. J Biol Chem 257:11416-11423.
30. Pike LJ and Lefkowitz RJ (1980) Activation and desensitization of β-adrenergic receptor-coupled GTPase and adenylate cyclase of frog and turkey erythrocyte membranes. J Biol Chem 255:6860-6867.
31. Remmers AE and Neubig RR (1996) Partial G protein activation by fluorescent guanine nucleotide analogs: Evidence for a triphosphate-bound inactive state. J Biol Chem 271:4791-4797.
32. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D and Miller LJ (1997) Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 51:357-362.
33. Samama P, Pei G, Costa T, Cotecchia S and Lefkowitz RJ (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:390-394.
34. 8α fusion protein. Eur J Biochem 255:369-382.
35. 8α has properties of a constitutively active receptor. J Biol Chem 273:5109-5116.
36. 2 receptors is not sensitive to GTP analogs. Mol Pharmacol 43:915-920.
37. Tucek S (1997) Is the R and R dichotomy real? Observations of allosteric phenomena on G protein-coupled receptors point to problems in the interpretation of agonist-receptor-G protein interactions. Trends Pharmacol Sci 18:414-416.
38. Wenzel-Seifert K, Hurt CM and Seifert R (1998a) High constitutive activity of the human formyl peptide receptor. J Biol Chem 273:24181-24189.
39. 8α GTPase activity. Biochem J 334:519-524.
40. 2S dopamine receptor: Evidence for multiple, agonist-specific active conformations. Mol Pharmacol 54:435-444.
41. Wild KD, Fang L, McNutt RW, Chang K-J, Toth G, Borsodi A, Yamamura HI and Porreca F (1993) Binding of BW 373U86, a non-peptidic δ opioid receptor agonist, is not regulated by guanine nucleotides and sodium. Eur J Pharmacol 246:289-292.
42. i1α fusion protein. Biochem J 325:17-21.
43. Wolff J and Cook H (1973) Activation of thyroid membrane adenylate cyclase by purine nucleotides. J Biol Chem 248:350-355.
44. Yu Y, Zhang L, Sun H, Uhl GR and Wang JB (1997) μ Opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 272:28869-28874.